Trial Profile

A two-part sham injection-controlled Phase IIb/III trial of Surabgene lomparvovec for Diabetic retinopathy

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 15 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surabgene lomparvovec (Primary)
Indications Diabetic retinopathy
Focus Therapeutic Use

Most Recent Events

11 Jan 2026 According to REGENXBIO media release, The Company will receive a $100 million milestone payment from AbbVie upon first patient dosed, expected 1H 2026.
11 Dec 2025 New trial record
06 Nov 2025 According to REGENXBIO media release, site selection for the trial is in progress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com